"Die im Kanton Bern beheimatete Insel Gruppe ist mit über 10 000 Mitarbeitenden das grösste medizinische Vollversorgungssystem der Schweiz und deckt von der Grundversorgung bis zur Spitzenmedizin alle Bereiche der Gesundheitsversorgung ab. Zur Gruppe gehören neben dem Universitätsspital Bern (Inselspital) auch das Stadtspital Tiefenau sowie die Landspitäler Aarberg, Belp, Münsingen und Riggisberg. Unsere Mitarbeitenden engagieren sich täglich in Medizin, Pflege, Betrieb, Infrastruktur, Verwaltung, Lehre und Forschung für das Wohl der jährlich rund 500 000 Patientinnen und Patienten. Wir investieren in eine umfassende Aus- und Weiterbildung, vermitteln Wissen in allen Bereichen der Medizin und fördern den akademischen Nachwuchs."

During the past decade, Insel Gruppe AG conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Insel Gruppe AG" #1 collaborator was "Baxter Healthcare Corporation" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator, "Carlos III Health Institute" with 1 trials as a collaborator and "Michael J. Fox Foundation for Parkinson's Research" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Insel Gruppe AG" are "Parkinson's Disease" (2 trials), "Aortic Valve Replacement in Patients With Moderate Aortic Stenosis Combined With Mitral Regurgitation" (1 trials), "Cardiogenic Shock" (1 trials), "Deep Brain Stimulation" (1 trials) and "Diffuse Large B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Insel Gruppe AG" in a lesser frequency.

Most popular intervention types in "Insel Gruppe AG" are "Drug" (3 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Atezolizumab Matching Placebo" (1 trials), "Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention" (1 trials), "Gemcitabine" (1 trials) and "Glofitamab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Insel Gruppe AG" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Insel Gruppe AG". 1 are not yet recruiting, 6 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Insel Gruppe AG, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Insel Gruppe AG, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".